The technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic biomarker discovery and development platform causing a share price gain of 15%.
Paris-based European venture capital company Truffle Capital closed its 250m BioMedTech fund celebrating its company building approach.
Data from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients.
The new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with 4.2m from mainly local investors, Augustine’s first priority is finding new therapeutics for patients suffering from Charcot-Marie-Tooth disease, a hereditary motor and sensory neuropathy of the peripheral nervous system.
French Transgene SA said it has terminated its lead programme TG4010 in combination with chemotherapy and checkpoint inhibition.
New research demonstrates that disruption of EGF receptor signalling allows commensal bacteria to invade hairs and cause skin lesions.
Madrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.
Swiss surgeons have significantly improved mechanical removal of blood clots in stroke patients by intra-arterial administration of the thromolytic urokinase.
Sanofi will acquire Synthorx Inc to expand its immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate.
Meatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the companys total funding to US$13m.